Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 21 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/7/2004 First Published: 8/24/2003


1.		Phase III Randomized Study of Oxaliplatin, Fluorouracil, and Leucovorin Calcium With or Without PTK787/ZK 222584 in Patients With Refractory or Recurrent Metastatic Adenocarcinoma of the Colon or Rectum

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0304011 NOVARTIS-CPTK787-0133/304946, NCT00068679


2.		Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				CPTK787 0135/306241 CONFIRM 1, NCT00056459


3.		PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				15 and over				Other				2004-0248 NCT00088231

Last Modified: 11/5/2007 First Published: 8/5/2005


4.		Phase I/II Randomized Study of Temozolomide and Radiotherapy With or Without Vatalanib in Patients With Newly Diagnosed Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 to 69				Other				EORTC-26041 EORTC-22041, EUDRACT-2004-003896-35, NCT00128700


5.		Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				CPTK787 0134/306220 NCT00171587

Last Modified: 5/1/2008 First Published: 3/13/2006


6.		Phase I/II Study of Vatalanib and Everolimus in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				DUMC-6626-04-12R0 NCT00303732

Last Modified: 4/9/2007 First Published: 2/10/2006


7.		Phase I/II Study of Docetaxel, Prednisone, and Vatalanib in Patients With Chemotherapy-Naive, Metastatic, Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				NCI				UCSF-04557 NCT00293371


8.		Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Temporarily closed				18 and over				Other				NVCI05-14 NCT00281125

Last Modified: 10/5/2006 First Published: 1/26/2003


9.		Phase II Study of PTK787/ZK 222584 in Patients With Unresectable Malignant Mesothelioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				Over 18				NCI				CALGB-30107 NCT00053885


10.		Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				UMCC 2005.014 NCT00134355

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute